pharma companies

“And I think we're seeing this more and more, where pharma companies will start to view themselves more as data generating companies. And data science companies as machine learning gets in,”

“Whatever the technology is, they got the cool technology, they think this will change drug design, and so then they go to pharma and they try to sell it. And pharma's not convinced yet. Ah, it's like my kids with new foods, and they don't want to try it until …”

“Pharma companies are swimming in targets, right? The problem they're trying to solve for is how do I fill in my pipeline?”

“The payers probably have more and better real-world data than the pharma companies do, and one of the reasons that the pharma companies will eventually, in my opinion, have to do data sharing, as Andrew suggests, is that the payers are going to aggregate their…”

“I think most acquisitions that you see in, in biotech are late stage to marketed stage companies, so they are, I think pharma companies are still very conservative in terms of making big bets on early stage platforms for acquisition.”

“So, so, you know, it's typical to You know, see pharma companies wait for proof of concept, you know, phase IIa data that shows safety and some efficacy before doubling down.”